U.S. Markets open in 9 hrs 10 mins

Enzyme PHLPP2 could be a viable drug target for treating prostate cancer

COLD SPRING HARBOR, N.Y., May 15, 2019 /PRNewswire/ -- An estimated 450,000 Americans are diagnosed each year with a cancer that's driven by MYC, an oncogene that hijacks growth and metabolism in cancer cells. MYC has a storied past of being notoriously hard for researchers to directly disable. "Now, we have a new way of getting at this old foe in cancer research," said Cold Spring Harbor Laboratory (CSHL) researcher Lloyd Trotman. And that's with an enzyme called PHLPP2 which presents a back-door route to target the gene.

Postmortem luciferase analysis confirms cancer metastasis to secondary organs. Photo Credit: Trotman lab/CSHL

Dr. Lloyd Trotman and his lab have been focused on understanding and searching for a cure for prostate cancer, one of the most prevalent cancers among men. It's the second leading cause of cancer death in American men. Prostate cancer can be confined to the organ, or the cancer cells can jailbreak the organ and metastasize to other parts of the body. Patients with cancers that have metastasized have a much lower rate of survival than if their cancer was contained in the organ. In a new study published in the Journal of Cell Biology, co-led by Dr. Trotman and Dr. Dawid Nowak, an assistant professor at Weill Cornell and a former postdoctoral fellow at the Trotman lab, researchers were able to halt the natural process of prostate cancer metastasis in mice by deleting the PHLPP2 enzyme.

PHLPP2 is the key to a signal pathway in the cell that controls cell growth and survival in response to extracellular communications and signal relays. It is required for prostate cancer progression to metastasis because it stabilizes and supports the MYC oncogene.

When the researchers completely blocked PHLPP2, they were able to stop prostate cancer growth and metastasis. Additionally, Trotman remarked that deleting this enzyme didn't manifest signs of toxicity in mice or human cells. This makes PHLPP2 an attractive drug target for treating prostate cancer, with possible applications across other types of cancers as well.

About Cold Spring Harbor Laboratory

Founded in 1890, Cold Spring Harbor Laboratory has shaped contemporary biomedical research and education with programs in cancer, neuroscience, plant biology and quantitative biology. Home to eight Nobel Prize winners, the private, not-for-profit Laboratory employs 1,100 people including 600 scientists, students and technicians. For more information, visit www.cshl.edu

Cision

View original content to download multimedia:http://www.prnewswire.com/news-releases/enzyme-phlpp2-could-be-a-viable-drug-target-for-treating-prostate-cancer-300848176.html